Jefferson Capital initiated with bullish views on collections edge

Investing.com -- Coverage of Jefferson Capital was started with bullish ratings by Wall Street analysts, who cited the company’s dominance in collecting low-balance consumer debts, strong returns, and expansion into new geographies and asset classes.

Citizens, KBW, and Jefferies each launched coverage with buy-equivalent ratings, setting price targets between $22 and $29.

Analysts pointed to JCAP’s differentiated business model, high barriers to entry, and consistent profitability since its founding in 2002.

Citizens initiated at Market Outperform with a $23 target, saying Jefferson has “cracked the code” on profitably collecting on hard-to-recover small-balance accounts.

The firm expects the company to outgrow peers due to its focus beyond traditional credit card charge-offs, with new seller relationships and a more flexible cost structure helping drive organic growth.

Citizens values the stock at ~9x 2026 EPS and sees a total return potential of 43%, including a 6% dividend yield.

KBW started coverage with an Outperform rating and $22 target, noting JCAP’s 46% ROE in 2024 (pro forma), well above peers.

Though ROE is expected to normalize to 30% by 2027, KBW flagged the company’s low leverage and room for faster deployment growth. It values the stock at 8x 2026 EPS of $2.74.

Jefferies was the most bullish, assigning a Buy and $29 price target, or 10x FY27 EPS, citing superior execution, regulatory track record, and international expansion.

The brokerage highlighted JCAP’s operations across the U.S., Canada, U.K., and Latin America, with plans to enter continental Europe.

Jefferies also pointed to favorable macro tailwinds as rising charge-offs create a rich supply of portfolios, while consumer payment rates remain stable.

Analysts flagged risks around regulation, pricing volatility, and macro shocks, but emphasized JCAP’s proven resilience and consistent returns.

You May Also Be Interested In

• Volkswagen plans to cut 50,000 jobs by 2030, shares gain
• PayPal cuts jobs in India and Ireland as it aims to simplify global operations
• Hutchmed surges on $1.3 billion GSK licensing deal